Kisspeptin

Kisspeptin is a family of naturally occurring human peptides produced from a precursor protein encoded by the KISS1 gene. The gene was first characterized in cancer biology, where its product was named metastin for its ability to suppress tumor metastasis. Its reproductive role was discovered later, and that is the role that now dominates the literature.

The precursor is cleaved into several active fragments that share an identical C-terminal decapeptide: kisspeptin-54, kisspeptin-14, kisspeptin-13, and kisspeptin-10. All of them bind the same G protein-coupled receptor, KISS1R, which older papers call GPR54. Because the shared C-terminal end is what engages the receptor, even the shortest fragment retains full intrinsic activity at the receptor.

What makes kisspeptin biologically distinctive is where it acts. It is not a gonadal hormone and it is not a pituitary hormone. Kisspeptin neurons sit in the hypothalamus, principally in the arcuate nucleus and the preoptic area, and they synapse onto GnRH (gonadotropin-releasing hormone) neurons. Kisspeptin is therefore an upstream switch: it tells GnRH neurons to fire, GnRH tells the pituitary to release LH and FSH, and LH and FSH tell the gonads to produce testosterone or estradiol and to mature gametes.

This upstream position is the reason kisspeptin is discussed differently from most peptides marketed to consumers. A peptide that acts at the top of a feedback loop can in principle recruit the body's own hormonal machinery rather than replace it. That is an interesting pharmacological idea, and it is a different idea from direct hormone administration. The same logic applies, in a different axis, to growth hormone secretagogues such as sermorelin, which act on the pituitary rather than supplying growth hormone itself.

Kisspeptin neurons also act as an integration hub. They carry receptors for sex steroids, which is how estradiol and testosterone exert feedback on the axis, and they are sensitive to metabolic and stress signals. This is the proposed mechanism linking undernutrition, intense training, chronic stress, and metabolic disease to suppressed reproductive function.

The clearest evidence for kisspeptin's necessity in human reproduction comes from genetics rather than from drug trials. In 2003, two independent groups published the finding that inactivating mutations in GPR54 cause normosmic idiopathic hypogonadotropic hypogonadism, a condition in which puberty does not occur despite an intact pituitary and intact gonads.

De Roux and colleagues, publishing in PNAS, identified a homozygous deletion of 155 nucleotides in GPR54 in affected siblings of a consanguineous family. Seminara and colleagues, publishing in the New England Journal of Medicine the same year, reported affected patients in an index pedigree homozygous for an L148S mutation in GPR54, plus an unrelated proband with two separate mutations. Their accompanying mouse work showed that Gpr54-deficient mice had isolated hypogonadotropic hypogonadism, with small testes in males and delayed vaginal opening and absent follicular maturation in females, while remaining responsive to exogenous gonadotropins and to GnRH itself, and retaining normal hypothalamic GnRH levels.

That last detail is the mechanistic crux. The GnRH neurons were present and the pituitary could respond. What was missing was the signal that tells GnRH neurons to release. Kisspeptin signaling is, in that sense, a permissive gate for puberty.

In adults, kisspeptin neurons are implicated in two distinct patterns of GnRH output. The first is the pulsatile release that sustains normal gonadal function day to day, attributed largely to arcuate nucleus kisspeptin neurons that co-express neurokinin B and dynorphin. The second is the mid-cycle LH surge that triggers ovulation in women, attributed to a population responsive to rising estradiol. The surge mechanism is precisely the property that fertility researchers have attempted to exploit, as discussed below.

It is worth stating the limit of this evidence plainly. Showing that a signaling pathway is required for normal reproduction is not the same as showing that adding the peptide to a healthy adult improves anything. Those are separate claims requiring separate trials, and the second claim is far less well supported.

Both fragments come from the same KISS1 precursor and both activate KISS1R through the same C-terminal decapeptide. The practical differences are length, circulating relevance, and duration of action.

Kisspeptin-54 is described in the clinical literature as the major circulating isoform of kisspeptin in humans. It is the form used in the large majority of the Imperial College London human trials, including the IVF trigger studies and the sexual desire imaging studies. Because it is longer, it is generally reported to produce a more sustained stimulation of the gonadotropin axis after a single administration.

Kisspeptin-10, often sold in research chemical channels as KP-10, is the ten-amino-acid C-terminal fragment: Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH₂, molecular formula C₆₃H₈₃N₁₇O₁₄, molecular weight approximately 1302.45 g/mol. It is fully active at the receptor but has a shorter plasma duration, which is why human studies using kisspeptin-10 have often relied on continuous infusion rather than a single bolus.

One nuance matters for anyone reading consumer marketing. Material sold online as kisspeptin is almost always kisspeptin-10, because it is cheaper to synthesize, while most of the headline human results that marketing cites were generated with kisspeptin-54 under hospital conditions. Those are not interchangeable claims. Potency at a receptor in vitro does not translate into equivalence of clinical effect, duration, or safety profile in a person.

Unlike most peptides discussed in the wellness space, kisspeptin has a real human literature, much of it produced by the group at Imperial College London led by Waljit Dhillo. The findings below are drawn from published, peer-reviewed trials, and each is deliberately described with its actual population and design rather than as a general claim.

Acute hormonal stimulation in men. Dhillo and colleagues reported in the Journal of Clinical Endocrinology and Metabolism in 2005 that a 90-minute intravenous infusion of kisspeptin-54 in male volunteers (n = 6) significantly increased plasma LH, FSH, and testosterone compared with saline infusion. The sample was very small, and the endpoint was a short-term hormone measurement, not a clinical outcome.

Desensitization with repeated dosing. This is the most important and least advertised human finding. Jayasena and colleagues reported in 2009 that subcutaneous kisspeptin-54 acutely stimulated gonadotropin secretion in women with hypothalamic amenorrhea, but that twice-daily administration over two weeks produced tachyphylaxis, meaning the response faded with repeated exposure. Receptor desensitization is a known behavior of this class of signaling, and it is the central obstacle to any chronic-use concept.

Tolerability across a pooled cohort. Mills and colleagues reported in the Journal of Clinical Endocrinology and Metabolism in 2025, in a double-blind, randomized, placebo-controlled crossover protocol involving 95 participants (63 male, 32 female), that kisspeptin administration robustly increased serum luteinizing hormone while state anxiety was not significantly altered compared with placebo.

Taken together, the human record supports a narrow and specific conclusion: administering kisspeptin to humans reliably stimulates the reproductive axis acutely, in a monitored setting, and has been reasonably well tolerated in short exposures. It does not support claims of sustained hormonal enhancement, and the tachyphylaxis finding argues directly against them.

In conventional IVF, final oocyte maturation is usually triggered with human chorionic gonadotropin (hCG), which mimics the natural LH surge. hCG has a long half-life and a prolonged action on the ovary, and in women with a high follicle count it carries a risk of ovarian hyperstimulation syndrome (OHSS), a potentially serious complication. The appeal of kisspeptin is that it triggers the woman's own LH surge, which is physiologically shorter-lived than an hCG stimulus.

Jayasena and colleagues published the first substantial test of this idea in the Journal of Clinical Investigation in 2014. Following superovulation with recombinant FSH and a GnRH antagonist to prevent premature ovulation, 53 women received a single subcutaneous injection of kisspeptin-54 at one of four dose levels (1.6, 3.2, 6.4, or 12.8 nmol/kg) to induce an LH surge and egg maturation. Egg maturation was observed at every dose tested, the mean number of mature eggs per patient generally increased in a dose-dependent manner, and fertilization followed by embryo transfer occurred in 92% (49 of 53) of treated patients.

Abbara and colleagues then focused specifically on the high-risk group, publishing in the Journal of Clinical Endocrinology and Metabolism in 2015. In this phase 2, multi-dose, open-label, randomized trial of 60 women at high risk of developing OHSS, oocyte maturation occurred in 95% (57 of 60) and embryo formation in 90% (54 of 60). The highest oocyte yield followed the 12.8 nmol/kg dose. Critically, the authors reported that no woman developed moderate, severe, or critical OHSS.

A follow-up phase 2 randomized controlled trial by the same group, published in Human Reproduction in 2017, found that a second dose of kisspeptin-54 improved oocyte maturation in women at high risk of OHSS.

Two caveats deserve emphasis. First, these were dose-finding trials without an hCG comparator arm, so they establish feasibility and a favorable observed safety signal rather than proving superiority over standard triggers. Second, every administration took place in a specialist fertility unit with monitoring, after a controlled stimulation cycle. None of this transfers to self-administration. Readers interested in how peptides are evaluated in women's health more broadly may find our overview of peptides studied in women a useful companion.

The interest is mechanistic and easy to state. Testosterone replacement therapy supplies the hormone from outside and, through negative feedback, suppresses LH, FSH, and endogenous testicular production, with the well-known consequences for testicular volume and spermatogenesis. A compound acting above GnRH would in theory raise testosterone by switching the native axis back on rather than overriding it.

There is one directly relevant human study. George and colleagues, publishing in Clinical Endocrinology in 2013, tested whether exogenous kisspeptin-10 could restore LH and testosterone secretion in hypotestosteronaemic men with type 2 diabetes. They reported increases in LH (from 3.9 ± 0.1 IU/l to 20.7 ± 1.1 IU/l, P = 0.03) and in testosterone (from 8.5 ± 1.0 to 11.4 ± 0.9 nmol/l, P = 0.002) in response to kisspeptin-10 infusion, concluding that kisspeptin-10 increased LH pulse frequency and LH secretion in this population.

The authors themselves described this as a proof-of-concept study, and that framing should be preserved. It was small, it used infusion rather than a practical self-administered format, and it measured short-term hormone concentrations rather than symptoms, body composition, fertility, or any patient-centered outcome. Nothing in it establishes that kisspeptin raises testosterone durably, that the effect persists beyond the infusion, or that it is safe or useful over weeks or months.

The desensitization result from the 2009 hypothalamic amenorrhea study is the direct counterweight to any chronic-use idea. If twice-daily exposure blunts the response within two weeks, then a simple daily regimen aimed at sustained testosterone elevation is biologically unpromising, and no published human trial has demonstrated otherwise. Investigators have explored intermittent and pulsatile schedules precisely because of this constraint, but those remain research questions rather than settled answers.

Important: low testosterone has many causes, including pituitary disease, medication effects, sleep apnea, and metabolic disease, and some of them are serious. It warrants proper endocrine evaluation rather than self-experimentation with an unapproved peptide.

A second strand of human research examined whether kisspeptin acts on brain circuits related to sexual and emotional processing, independently of its hormonal effects. These studies used functional MRI with placebo-controlled designs, which is unusual rigor for this field.

Comninos and colleagues published the first of these in the Journal of Clinical Investigation in 2017. Comparing kisspeptin with vehicle administration in 29 healthy heterosexual young men, they found that kisspeptin enhanced limbic brain activity specifically in response to sexual and couple-bonding stimuli, and that these changes correlated with psychometric measures of reward, drive, mood, and sexual aversion.

Thurston and colleagues extended this to a clinical population in JAMA Network Open in 2022. In a double-masked, placebo-controlled, two-way crossover trial conducted in a UK university research setting from October 2020 to April 2021, 40 premenopausal women with hypoactive sexual desire disorder (HSDD) were randomized and 32 completed both the kisspeptin and placebo visits. Kisspeptin administration modulated sexual and facial attraction brain processing on functional neuroimaging, and the authors reported that kisspeptin was well tolerated and produced no adverse effects after infusion.

Mills and colleagues published the male counterpart in JAMA Network Open in 2023. Thirty-two men with HSDD completed a double-blind, two-way crossover, placebo-controlled trial of intravenous kisspeptin-54 at 1 nmol/kg/h or placebo for 75 minutes. Kisspeptin modulated activity in the sexual-processing network and increased penile tumescence in response to visual sexual stimuli by up to 56% over placebo, alongside improvements in behavioral measures of sexual desire and arousal.

These are genuinely interesting results, and they are also mechanistic studies of roughly 30 people each, measuring brain activation and acute physiological response over a single session. They are not efficacy trials. No regulator has reviewed kisspeptin for HSDD, no phase 3 program has reported, and no clinically meaningful durable benefit on sexual function has been established. Readers should treat the gap between modulating brain processing in a scanner and treating low libido as large and currently unbridged.

Across the published human trials, kisspeptin has generally been described as well tolerated in short, supervised exposures. The Thurston 2022 trial in women with HSDD reported that kisspeptin was well tolerated with no adverse effects after infusion. The Mills 2025 pooled crossover protocol in 95 participants found no significant effect on state anxiety versus placebo, addressing one specific concern raised by animal work on kisspeptin and anxiety-like behavior.

That favorable record comes with important boundaries. Nearly all of it derives from single or short-course administration in hospital settings, with screened participants, defined formulations, and clinical monitoring. There is no published long-term human safety data for kisspeptin. The duration of the longest published human exposures is measured in weeks, not years.

The best-characterized pharmacological limitation is not a toxicity but a loss of effect: tachyphylaxis. Repeated twice-daily subcutaneous kisspeptin-54 over two weeks blunted the gonadotropin response in women with hypothalamic amenorrhea. Any regimen built on frequent dosing should be expected to encounter this.

Several theoretical concerns follow from the mechanism rather than from reported events. Kisspeptin stimulates the entire reproductive axis, so effects on menstrual cyclicity, ovulation timing, and fertility are plausible and are not something to provoke casually. Anyone with a hormone-sensitive condition, a pituitary disorder, a history of precocious or delayed puberty, or who is pregnant or trying to conceive falls outside every published trial population.

There is also a product-quality dimension that has nothing to do with the peptide itself. Material purchased through research chemical channels is not pharmaceutical grade, is not subject to regulatory manufacturing oversight, and may differ from its label in identity, purity, sterility, or content. Our article on whether peptides are safe covers that distinction in more detail. This section is informational and is not a safety clearance for use. Consult a healthcare professional.

Kisspeptin is not approved as a medicine by the FDA, the EMA, or any comparable regulatory authority for any indication, in any country we are aware of as of this writing. There is no licensed kisspeptin product, no approved label, no official dosing information, and no authorized clinical protocol. Everything described in this guide took place within investigational clinical trials.

The practical consequence is that there is no such thing as a correct kisspeptin dose outside a trial. Published studies used specific doses under investigational protocols, with ethics committee approval, clinical monitoring, and pharmaceutical-grade material prepared for that purpose. Those numbers are reported here as study descriptions, not as guidance, and this guide deliberately gives no dosing, administration, or protocol recommendations of any kind.

In the United States and the European Union, peptides in this situation are typically distributed labeled for research use only, which is a legal classification that explicitly excludes human use. That label is not a quality claim and not an endorsement of safety. Legal status also varies by jurisdiction, and importing or possessing such material may carry consequences that differ substantially from one country to another.

For athletes, there is an additional consideration. Substances that stimulate the hypothalamic-pituitary-gonadal axis fall within the scope of anti-doping regulation, and the World Anti-Doping Agency's prohibited list addresses peptide hormones, growth factors, and hormone and metabolic modulators. Anyone subject to testing should verify the current list directly with their governing body rather than relying on secondary sources.

Finally, the absence of approval is not an indictment of the science. Kisspeptin has a credible research program behind it, and the IVF work in particular is serious clinical investigation. The point is narrower: promising trial data and an approved therapy are separated by a long evidentiary road, and kisspeptin has not traveled it.

Kisspeptin and PT-141 (bremelanotide) are both discussed in connection with low sexual desire, which makes them easy to confuse. They act on entirely different systems and occupy entirely different regulatory positions.

PT-141, or bremelanotide, is a melanocortin receptor agonist. At therapeutic dose levels it activates melanocortin receptors including MC4R in the brain, engaging neural circuits involved in sexual desire and arousal. It is not a reproductive-axis hormone and does not meaningfully drive LH, FSH, or testosterone. Marketed as Vyleesi, it received FDA approval on June 21, 2019, for premenopausal women with acquired, generalized hypoactive sexual desire disorder characterized by low sexual desire causing marked distress or interpersonal difficulty. Its label explicitly states that it is not indicated for HSDD in postmenopausal women or in men.

Kisspeptin acts on KISS1R upstream of GnRH. Its hormonal effects are its defining property, and its sexual-processing effects were observed in small mechanistic fMRI trials in both men and women with HSDD. It has no approval anywhere.

The honest summary is that these two are not competitors in the same evidentiary tier. One is an approved prescription product with a defined indication and a published label; the other is an investigational peptide with genuinely interesting but early mechanistic data. Any decision about sexual desire concerns belongs with a clinician who can evaluate the many non-peptide causes first, including relationship factors, depression, medication effects, thyroid disease, and hormonal disorders.

Medical disclaimer: This article is for educational purposes only and does not constitute medical advice, a dosing recommendation, or a protocol. Kisspeptin is not approved for human use. Consult a qualified healthcare professional before making any decision related to your health.